Navigation Links
AEterna Zentaris Announces Results from Two Phase 3 Studies with Cetrorelix in Benign Prostatic Hyperplasia
Date:8/17/2009

rorelix pamoate in patients with symptomatic BPH: an open-labeled safety and efficacy assessment study". It is a multi-center, open-label, single-armed study involving 528 patients in North America. The lead investigator was Joel Kaufman, M.D., Associate Clinical Professor in Urology at University of Colorado School of Medicine in Denver, Colorado and at Urology Research Options in Aurora, Colorado.

Results of the second efficacy trial Z-036 are scheduled to be disclosed during the fourth quarter of this year.

About Cetrorelix

Cetrorelix pamoate is an investigational agent that has shown in Phase 2 studies to provide fast and long lasting relief of BPH symptoms and was well tolerated, with a low incidence of sexual side effects. Cetrorelix is part of AEterna Zentaris' luteinizing hormone-releasing hormone (LHRH) antagonist therapeutic approach. This peptide-based active substance was developed by the Company in cooperation with Nobel Prize winner Prof. Andrew Schally, currently of the U.S. Veterans Administration in Miami.

Cetrorelix acetate is marketed under the brand name Cetrotide(R), the first LHRH antagonist approved for therapeutic use as part of in vitro fertilization programs (controlled ovulation stimulation/assisted reproductive technologies) in Europe, the USA and Japan. It was launched on the market through Serono (now Merck Serono) in the U.S., Europe and in several other countries, as well as in Japan through Shionogi.

About Benign Prostatic Hyperplasia

Benign prostatic hyperplasia (BPH) is one of the most common diseases of aging men - affecting more than 20 million men in the United States - but its etiology is far from being completely understood. Data from ongoing research suggest BPH and lower urinary tract symptoms (LUTS) are more complex conditions than once thought. While previous research on BPH etiology tended to focus on testosterone and other horm
'/>"/>

SOURCE AETERNA ZENTARIS INC.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. AEterna Zentaris Reports Second Quarter 2009 Financial and Operating Results
2. AEterna Zentaris to Present at Upcoming Canaccord Adams 29th Annual Global Growth Conference
3. AEterna Zentaris to Announce Second Quarter 2009 Financial and Operating Results on August 11, 2009
4. AEterna Zentaris Partner, Keryx, Announces Agreement with FDA on a Special Protocol Assessment for Phase 3 Trial with Perifosine (KRX-0401) for the Treatment of Multiple Myeloma
5. AEterna Zentaris: New Data Published on its Ghrelin Antagonist Compound, AEZS-123 (JMV2959), Supports its Use in Alcohol Addiction
6. AEterna Zentaris Receives US$10 Million from Institutional Investors
7. AEterna Zentaris to Report Data from Safety Study of Phase 3 Program in Benign Prostatic Hyperplasia with Cetrorelix Ahead of Schedule
8. AEterna Zentaris Opens Extended Study for Cetrorelix in Benign Prostatic Hyperplasia
9. AEterna Zentaris Discloses Preliminary Phase 2 Trial Results for Perifosine in Combination with Radiotherapy for Non-Small Cell Lung Cancer
10. AEterna Zentaris Acquires All Assets from Ardana for Growth Hormone Secretagogue Compound, AEZS-130
11. AEterna Zentaris Presents Data Supporting Evaluation of AEZS-108 in Prostate Cancer at ASCO Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2015)...  Turing Pharmaceuticals AG announced that life sciences executive ... MSc,  has joined the company as president of ... holds a medical degree as well as a ... accomplishments in the pharmaceutical industry, and extensive clinical ... played a leadership role in numerous programs for ...
(Date:6/1/2015)... and RARITAN, N.J. , ... LLC (Janssen) announced data from the Phase 3 ... in progression-free survival (PFS) with trabectedin (YONDELIS ® ... liposarcoma (LPS) or leiomyosarcoma (LMS) previously treated with ... regimen. SAR3007 is the largest randomized Phase 3 ...
(Date:6/1/2015)... 1, 2015 /PRNewswire/ - BIOREM Inc. (TSX-V: BRM) ("Biorem" or "the Company") ... 2015.  Biorem,s complete 2015 first quarter financial statements and MD&A have ... ended March 31,(in CDN$,000 except per share data) , ... , 1,974 Gross profit , 1,531 , ... (loss) , 528 , (531) Basic earnings (loss) ...
(Date:6/1/2015)... , June 1, 2015  The Val Skinner ... national innovative science curriculum for high school students focused ... 16 th annual LIFE Event (LPGA Pros in ... Ridge Country Club in West Caldwell, N.J. ... LPGA,s biggest stars raised more than $500,000 on Monday, ...
Breaking Biology Technology:Turing Pharmaceuticals Names Eliseo Salinas, MD and MSc, President of Research and Development 2Turing Pharmaceuticals Names Eliseo Salinas, MD and MSc, President of Research and Development 3Trabectedin Improves Disease Control in Patients with Advanced Soft Tissue Sarcoma 2Trabectedin Improves Disease Control in Patients with Advanced Soft Tissue Sarcoma 3Trabectedin Improves Disease Control in Patients with Advanced Soft Tissue Sarcoma 4Trabectedin Improves Disease Control in Patients with Advanced Soft Tissue Sarcoma 5Trabectedin Improves Disease Control in Patients with Advanced Soft Tissue Sarcoma 6Biorem Reports Increased Revenues and Earnings for First Quarter 2Biorem Reports Increased Revenues and Earnings for First Quarter 3Val Skinner Foundation Announces Partnership With Discovery Education 2
... England, April 21 Paul Capital,Healthcare and Vernalis ... a financing agreement relating to frovatriptan, Vernalis, product,for ... will receive,approximately euro 18.4 million in cash from ... will receive approximately 90 per cent,of Menarini,s payments ...
... MIT Lincoln Laboratory have developed a powerful sensor ... and smallpox in less than three minutes. , ... for THreatening Environmental Releases), represents a significant advance ... Lincoln Lab,s Biosensor and Molecular Technologies Group. Current ...
... b3c newswire /   -  DuoCort AB announced ... Optimized Care for Adrenal Insufficiency – at the 10th ... Congress Centrum in Berlin.  The symposium will be held ... delegates attending ECE 2008 are invited to the symposium. ...
Cached Biology Technology:Vernalis and Paul Capital Healthcare Sign euro 18.4 Million Financing Agreement 2Vernalis and Paul Capital Healthcare Sign euro 18.4 Million Financing Agreement 3MIT's PANTHER sensor quickly detects pathogens 2DuoCort Hosts Adrenal Insufficiency Symposium at the 10th European Congress of Endocrinology in Berlin 2
(Date:5/7/2015)... 7, 2015 Fingerprint Cards ... and FPC1035, FPC,s smallest touch fingerprint sensors to ... considered for integration on the backside of the ... increased possibilities to integrate touch fingerprint sensors in ... improves possibilities for module manufacturers to customize the ...
(Date:4/27/2015)... Apr. 27, 2015 Profile Solutions, Inc. (OTC: ... security systems is pleased to announce that Dr ... consultant and member of its scientific advisory board. ... as a thought leader in technology-enhanced learning models. He ... and has published studies and books focused on online ...
(Date:4/14/2015)... , April 14, 2015  HYPR Corp. ... Online (FIDO ® ) Alliance tm , an ... FIDO members commit to share technology and collaborate ... that are interoperable, more secure and private, and ... biometric identity verification that protects sensitive user information ...
Breaking Biology News(10 mins):FPC Introduces its Smallest Touch Fingerprint Sensors to Date 2Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 2Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 4HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3
... the cells of blood vessels running through ovarian tumors. ... diagnosis and treatment for this disease. , The team ... Pennsylvania, and universities in Greece and Italy, used a ... ovarian tumors and four normal ovarian tissue samples. From ...
... markedly in their response to sleep deprivation, but the ... identify. Researchers have now found that a genetic difference ... particularly sensitive to the effects of sleep deprivation. The ... at the University of Surrey's Sleep Research Center, appear ...
... machine of their design, Duke University Medical Center researchers ... improve the ability of physicians to repair damaged joints ... experiments are successful, the scaffold could be used in ... Moutos, a graduate student in the Orthopedic Bioengineering Laboratory ...
Cached Biology News:Researchers identify ovarian cancer biomarkers 2Individual differences in a clock gene predict decline of performance during sleep deprivation 2Woven scaffolds could improve cartilage repair 2
... system is used for conventional PCR and ... MyCycler personal thermal cycler, which features a ... ml tubes or plates, programmable time, temperature, ... block modes of temperature control. The system ...
... Ciphergen's ProteinChip arrays have been ... from biological samples. A variety of ... of proteins according to their unique ... different spots, allowing side-by-side sample comparison, ...
The Freeze 'N Squeeze DNA gel extraction kit uses a quick freeze-and-thaw cycle and centrifugation to draw 50-23,000 bp DNA out of agarose gel slices. The kit includes materials for 100 preps....
The Econo gradient pump rack is a preassembled rack that is used to hold the components of the Econo gradient pump kits....
Biology Products: